Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KD6-287 Phase III Study
jRCT2031240307Phase 3Completed
- Sponsor
- KM Biologics
- Start
- Oct 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, single-arm trial of KD6-287 in Japanese encephalitis (JE), sponsored by KM Biologics. Primary endpoint: Seroconversion rate of neutralizing antibodies after the third dose. Started Oct 2024; status: completed.
02
Drugs
KD6-287
03
Conditions
Japanese encephalitis (JE)
Beyond the preview
Go deeper on jRCT2031240307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240307.